Digene
This article was originally published in The Gray Sheet
Executive Summary
Hybrid Capture II test will be available in May following FDA clearance of the test as an adjunct to Pap smear screening, the firm announces March 19. Digene estimates the U.S. market for borderline Pap smear testing at $70 mil